Design Therapeutics Competitors and Similar CompaniesClear all
Design Therapeutics's competitors and similar companies include Abliva, Y-mAbs Therapeutics, Prevail Therapeutics and Thor Medical.
 Design Therapeutics Design Therapeutics is a biopharmaceutical company engaged the research and development of small-molecule gene targeted chimera therapeutic candidates. |  Abliva Abliva is a biotech company that discovers and develops medicines for the treatment of mitochondrial disease. |  Y-mAbs Therapeutics Y-mAbs Therapeutics is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets. |  Prevail Therapeutics Prevail Therapeutics is a biotech company that is developing therapeutics for neurodegenerative disorders, such as Parkinson's disease. |  Thor Medical Thor Medical (formerly known as Nordic Nanovector) is a biopharmaceutical company that focuses on the development and commercialisation of novel targeted therapeutics in haematology and oncology. | |
Founding Date | Founding Date 2017 | Founding Date 2000 | Founding Date 2014 | Founding Date 2017 | Founding Date 2009 |
Type | Type Public | Type Subsidiary | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Carlsbad, US HQ | Locations Lund, SE HQ | Locations New York, US HQ Copenhagen, DK Nutley, US | Locations New York, US HQ | Locations Oslo, NO HQ Zug, CH Shrewsbury, GB |
Employees | Employees 54 | Employees 950% increase | Employees 3239% increase | Employees 489% increase | Employees 3716% decrease |
Valuation ($) | Valuation ($) 313.1 m | Valuation ($) N/A | Valuation ($) 657 m | Valuation ($) 787.7 m | Valuation ($) 131.4 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $87.7m (FY, 2024) | Revenue (est.) N/A | Revenue (est.) kr439k (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods $15m (FY, 2024) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit kr497k (FY, 2024) | Gross profit $72.7m (FY, 2024) | Gross profit N/A | Gross profit kr4.3m (FY, 2025) |
Net income | Net income ($69.8m) (FY, 2025) | Net income (kr90m) (FY, 2024) | Net income ($29.7m) (FY, 2024) | Net income ($63.2m) (FY, 2019) | Net income (kr58m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 45m | Total funding raised $ 10.8m | Total funding raised $ 80m | Total funding raised $ 125m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Abliva
HQ
Lund, SE
Abliva is a biotech company that discovers and develops medicines for the treatment of mitochondrial disease.
View companyY-mAbs Therapeutics
HQ
New York, US
Employees
32↑ 39% increase
Y-mAbs Therapeutics is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets.
View companyPrevail Therapeutics
HQ
New York, US
Employees
48↑ 9% increase
Prevail Therapeutics is a biotech company that is developing therapeutics for neurodegenerative disorders, such as Parkinson's disease.
View companyThor Medical
HQ
Oslo, NO
Employees
37↓ 16% decrease
Thor Medical (formerly known as Nordic Nanovector) is a biopharmaceutical company that focuses on the development and commercialisation of novel targeted therapeutics in haematology and oncology.
View company